2 directorsHidden nameVisible after signing in and 1 other
Documentsfilings and deeds
09-07-202622 days before the deadline
2025abbreviated format
Gross margin from €200,413 to €295,086Result from €7,075 to €71,664Dividend €140,000Equity from €97,762 to €29,426Debts from €120,290 to €203,100Investments €5,368
Less equity than 84% of companies in retail trade. Sector median €314,713 · 13,258 companies.
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 6,715 companies had the same profile as JLS Pharma has now. Each dot stands for 17 companies, two years later.
95.8%
were still trading
2.2%
stopped another way
1.8%
went bankrupt
Micro
5 to 10 years old
solvency 10 to 30%
a profit of 5% of the balance sheet or more
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.3%
0.5%
3
0.5%
0.6%
4
0.7%
0.8%
5
0.9%
0.9%
6
1.3%
1.5%
7
1.6%
1.8%
8
1.8%
1.8%
9
2.9%
3.1%
10
5.6%
6.1%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,715 companies, not a prediction for JLS Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
Registered office moved from Louveigne to Meux
The registered office moved from Rue de la China 29, 4141 LOUVEIGNE to Rue des Closières 21 à 5081 Meux · Appointment: Name hiddenVisible after signing in (director) · General meeting of 30.09.25 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0771655091
Share cancellation
Cancellation of 4 shares · General meeting of 11-10-2022 · Gazette deed
First establishment
Büllinger Strasse 8, Butgenbach
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as JLS Pharma: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €200,000 and €439,000, founded between 2014 and 2023.
The company number of JLS Pharma is 0771.655.091. The VAT number is the same number with BE in front: BE 0771.655.091.
Where is JLS Pharma based?
The registered office is at Rue des Closières, Meux 21, 5081 La Bruyère.Company details
What does JLS Pharma do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of JLS Pharma?
JLS Pharma is a private limited company (BV).
When was JLS Pharma founded?
JLS Pharma was founded on 23-07-2021.
Is JLS Pharma still active?
Yes, JLS Pharma is an active enterprise in the KBO register.
How many employees does JLS Pharma have?
JLS Pharma had an average of 2.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of JLS Pharma?
The turnover in financial year 2025 is ≈ €1.0m. This figure is estimated from the gross margin of €295,086 and 42 comparable companies (NACE 477). It probably lies between €800,000 and €1.4m. In financial year 2023 turnover was €1.0m.
Is JLS Pharma profitable?
In financial year 2025, JLS Pharma made a profit of €71,664.
Where can I find the annual accounts of JLS Pharma?
JLS Pharma filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of JLS Pharma due?
JLS Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline